How to fix a BRCA1/2 gene mutation that causes cystic fibrosis: The cure is a little-known gene
A new study has found that if you have a BCR-ABL mutation, you can potentially be cured of cystic Fibrosis by changing your DNA.
Researchers from Columbia University, the University of Texas Southwestern Medical Center and the Johns Hopkins Bloomberg School of Public Health found that those with a mutation in the BRCAS1 and 2 gene were twice as likely to have a favorable prognosis when it came to the progression of their disease.
This suggests that these individuals could potentially benefit from a gene therapy that targets the BCR and the Bcl-2 genes, which are also involved in the production of Bcl genes, the enzymes that help break down collagen.
“Our study shows that in people with a Bcl gene mutation, we can potentially make the disease go away,” said senior author and PhD student, Michael R. Schurman, M.D., Ph.
D. “This is a very novel approach, and it could potentially have tremendous implications for many patients.
This could be one of the first times in the history of medicine that people with BCR mutations have been shown to be able to improve their health.”
The researchers first found that BCR2 mutations were linked to about 1 in 4 people with cystic cystic disease, and were also associated with elevated risk for type 2 diabetes and cardiovascular disease.
The BRCAs2 gene is the main transcription factor responsible for converting Bcl to Bax.
Schorman and his team also found that patients with a high BRCAC1 level also had an increased risk for Type 2 diabetes.
The research team was able to identify a gene that is likely to be involved in BCR gene function and found it to be the Bcr1 gene.
Schourman said that Bcr genes are key regulators of the body’s immune system, and the gene that regulates Bcr gene function is also involved with the production and clearance of Bax, a substance that is required for the formation of collagen.
“There are some Bcr2 gene variants, and these are known to be associated with risk for developing certain inflammatory diseases,” Schormen said.
“But we also found a gene variant that is associated with a significantly higher risk for diabetes, and that variant is associated to a significantly lower likelihood of having a favorable outcome.”
A BRCAL gene mutation causes the immune system to produce antibodies, which can then trigger a cascade of events that lead to the formation and maintenance of collagen in the body.
“We are interested in studying the interactions between the immune response and the collagen production, so we need to look at the BrcA2 and BcrA2 genes as well as the Bax genes, because those are key players in the process,” Schurmen said, adding that it was difficult to get a high level of accuracy in these tests.
Schorman’s team found that people who had mutations in the two genes were twice more likely to develop the disease, with a 25% increased risk of developing the disease compared to the control group.
Schouman’s research team also discovered that the mutations increased the likelihood of the patient’s body rejecting the BRS-1 gene, a gene in the bone marrow that has been linked to bone loss and inflammation.
This gene was also found to be linked to a higher risk of having certain types of cancer.
“This study is the first to suggest that these two genes are associated with the development of a Bcr mutation that can be beneficial,” Schoumans said.
“And, interestingly, these mutations increase the risk for the patient to develop Type 2 Diabetes.
That is a big potential benefit, but we don’t know if it would be as important for the patients with Type 2 Diabetes.”
The study was published online by Nature Medicine on May 15.
It is available at www.nature.com/articles/srep1726.